| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Imatinib | CTRPv2 | pan-cancer | AAC | -0.029 | 0.4 |
| mRNA | tivantinib | CTRPv2 | pan-cancer | AAC | -0.036 | 0.4 |
| mRNA | Parthenolide | GDSC1000 | pan-cancer | AAC | -0.042 | 0.4 |
| mRNA | staurosporine | CTRPv2 | pan-cancer | AAC | 0.057 | 0.4 |
| mRNA | TAE684 | GDSC1000 | pan-cancer | AAC | 0.042 | 0.4 |
| mRNA | BMS-195614 | CTRPv2 | pan-cancer | AAC | 0.03 | 0.4 |
| mRNA | ELCPK | CTRPv2 | pan-cancer | AAC | -0.039 | 0.4 |
| mRNA | BRD-K58730230 | CTRPv2 | pan-cancer | AAC | 0.058 | 0.4 |
| mRNA | CUDC-101 | GDSC1000 | pan-cancer | AAC | 0.024 | 0.4 |
| mRNA | tanespimycin:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.029 | 0.4 |